Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03653936 · ClinicalTrials.gov registry record
Neuro-ocular Baselines in a Sports Setting
A clinical trial, sponsored by Rebiscan.
- Completed
- Registry status
- 63
- Enrollment target
NCT03653936: Completed study, sponsored by Rebiscan.
NCT03653936 is a clinical trial that has completed, run by Rebiscan. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03653936 has completed, sponsored by Rebiscan.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
Rebion (Rebiscan, Inc) has developed a noninvasive, handheld device that uses retinal birefringence scanning (RBS) to rapidly assess eye fixation and retinal integrity in adults and children. The proprietary technology uses a scanned annulus of polarized laser light to create a signature that confirms central fixation within seconds. The project described herein aims to provide accurate assessment of brain dysfunction in TBI (Traumatic Brain Injury) patients through the use of the developed device, which is called the Head and Intraocular Trauma Test (HITT) device.
Primary Outcome
Screening device will provide a wave form calculation of light reflecting off patient's eye
Interventions
- DEVICE HITT device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2018-11-30 |
What the finished NCT03653936 record still lists
NCT03653936 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which HITT device is the first listed.
NCT03653936 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03653936 about?
NCT03653936 is a clinical study titled "Neuro-ocular Baselines in a Sports Setting". Rebion (Rebiscan, Inc) has developed a noninvasive, handheld device that uses retinal birefringence scanning (RBS) to rapidly assess eye fixation and retinal integrity in adults and children. The proprietary technology uses a scanned annulus of polarized laser light to create a signature that confir...
What is the current status of trial NCT03653936?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2018-04-01. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03653936?
The interventions under investigation include: HITT device (DEVICE).
Who is sponsoring clinical trial NCT03653936?
This trial is sponsored by Rebiscan, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI